Ono Pharmaceutical And Astellas Launch Osteoporosis Drug
This article was originally published in PharmAsia News
Executive Summary
Osaka-based Ono Pharmaceutical and Tokyo-based Astellas April 7 launched osteoporosis drug RECALBON/Boneteo (minodronic acid) in Japan. Jointly developed by the two, the treatment obtained Japanese approval Jan. 21. The side effects include stomach and abdominal discomfort, abdominal pain, reduced blood calcium and gastritis. Severe side effects include duodenal and gastric ulcers. (Click here for more - Japanese language